New Study to Explore How Erchonia’s Low Level Lasers Affect Chronic TMJ Pain
Erchonia announces a new preliminary study to explore how its non-invasive, low level laser technology affects chronic pain caused by temporomandibular joint disorders, or TMJ.
McKinney, TX (PRWEB) June 14, 2013
Erchonia announces a new preliminary study to explore how its non-invasive, low level laser technology affects chronic pain caused by temporomandibular joint disorders, or TMJ. The preliminary study will apply a new prototype of Erchonia´s low level laser to approximately 20 patients. If the study finds a statistically significant result, Erchonia will move on to do an independent samples study with a placebo control.
As with any IRB study, strict patient selection criteria will be followed in the preliminary study. Potential subjects must already be diagnosed with TMJ by a qualified medical professional. Next, they will rank their own pain on the VAS scale from 0 to 100–100 being the most painful. To qualify for the study, their ratings must be 40 or higher and must have lasted for at least three months. Subjects must also have experienced their chronic pain at least 50% of the time and have limited oral motion of no more than 40 mm. They cannot have had dental treatment or surgery for a reasonable time before or after the study.
Dr. Robert Burke, who will serve as the lead investigator for the study, comments, “Approximately 45% of the U.S. population suffers from some kind of chronic pain. I hope this study allows for a new focus on intense pain to improve quality of life for those who suffer from severe chronic pain such as TMJ. Erchonia has been great about pushing the boundaries of what its lasers can do. Without Erchonia´s prototype, this study wouldn´t be possible.”
Other Erchonia low level lasers have been previously studied and cleared by the FDA for chronic neck and shoulder pain treatment; for liposuction and breast augmentation assistance and the reduction of associated pain; for the treatment of acne; and for circumference reduction of the arms and the waist, hips and thighs.
For more information, please visit http://www.erchonia.com.
Erchonia is the global leader in low level laser healthcare applications. Over the last 15 years Erchonia has been conducting research and development with the world´s leading physicians to advance the science of low level lasers. Prior to market introduction, all Erchonia lasers are proven safe and effective through independent clinical trials. Currently thousands of Erchonia´s lasers are used daily to reduce body fat, eliminate pain, and treat acne. For additional information, visit http://www.erchonia.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/6/prweb10829578.htm